Bioventus Inc. (BVS)
Dopo ore:
| Chiusura precedente | 7,45 |
| Aperto | 7,59 |
| Denaro | 5,51 x 200 |
| Domanda | 7,50 x 400 |
| Min-Max giorno | 7,33 - 7,59 |
| Intervallo di 52 settimane | 2,82 - 7,67 |
| Volume | |
| Media Volume | 521.993 |
| Capitalizzazione | 476,792M |
| Beta (mensile su 5 anni) | 0,84 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,33 |
| Prossima data utili | 06 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 8,50 |
GlobeNewswireBioventus to Present at the Cantor Global Healthcare Conference
DURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 1:50 p.m. ET. A live audio webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be availabl
- GlobeNewswire
Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2023, at 8:50 a.m. ET. A live audio webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be available for replay o
- GlobeNewswire
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023. Q2 Financial Summary: Net Sales of $137.1 million, down $3.3 million, or 2.3%, year-over-year as reported (2.3% constant currency*), excluding revenues from divested assets, underlying organic sales decreased $0.5 million, or 0.3% year-over-yearNet Loss from
